Form 4: UroGen Pharma Executive Schoenberg Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer Mark Schoenberg reports acquisition and disposal of UroGen Pharma shares related to restricted stock units.
Summary
- Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd., reported transactions involving the company's ordinary shares on September 9, 2024.
- These transactions involved the vesting and subsequent sale of shares to cover withholding tax obligations related to restricted stock units (RSUs).
- Schoenberg acquired 1,666 shares through the vesting of RSUs and sold 859 shares at a price of $13.08 per share to cover tax obligations.
- Following these transactions, Schoenberg directly owns 145,091 ordinary shares and 3,334 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and prospects.
Key Dates
| Date | Description |
|---|---|
| 09/07/2023 | Reporting person was granted RSUs representing 5,000 ordinary shares. |
| 09/09/2024 | Date of earliest transaction: Acquisition of 1,666 shares via RSU vesting and sale of 859 shares. |
| 09/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.